Psyence Biomedical Ltd PBM

$2.93 +0.07 (2.45%)

Valuation

Market cap
5,756,000
Revenue TTM
$0
Net income TTM
$-6,940,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
29,948
Avg volume
69,554
Day's range
$2.70 – $3.00
Shares out
2,293,000
Stochastic %K
45%
Beta
1.72
Analysts
—
Price target
—

Price

Company profile

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiar...

Show more

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
416-477-1708
Website
https://psyencebiomed.com
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada

Latest news

No headlines yet.